Theodore Voorhees, who served as Chair of the ABA Antitrust Section in 2012-2013, is a senior antitrust advisor and litigator in the firm’s Washington, DC office representing clients in the e-commerce, chemicals, outdoor sports equipment and apparel, food and beverage and agricultural commodities industries, among others. Much of Mr. Voorhees’ antitrust advisory work focuses on pricing and distribution arrangements in the United States, and counseling trade associations on antitrust compliance matters. On consumer protection matters, Mr. Voorhees has represented clients in proceedings before the Federal Trade Commission on advertising and marketing matters and before the Consumer Product Safety Commission on product safety matters. He has advised clients on advertising substantiation and the legal issues posed by the emerging field of neuromarketing. Mr. Voorhees’ practice also encompasses risk assessment, risk management and litigation defense in product liability and toxic tort matters, especially industry-wide risks posed by emerging technologies. He has counseled corporate and trade association clients on product liability risk assessment and management in the nanotechnology, software, mining, medical devices, construction equipment, pharmaceutical, chemical, food, and beverage alcohol industries. Mr. Voorhees has lectured at numerous conferences on a broad range of risk assessment issues including nanotechnology, the growing controversy over the causes of the obesity epidemic, and product liability risks facing trade associations that lobby the government on health and safety matters.
412 | Events
On April 22nd, the DC Circuit Court of Appeals set aside the FTC’s 2006 decision that Rambus Inc. unlawfully monopolized four technology markets through deceptive conduct during the JEDEC standards development process for two widely-implemented computer memory standards. The Court held that (...)
On April 4, 2006, the FTC published notice of its intention to conduct an extensive study of the economic effects of authorized generic pharmaceuticals. See 71 Fed. Reg. 16,779 (April 4, 2006). The initial stage of the study would involve detailed information requests, akin to subpoenas, to as (...)